Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epcoritamab + rituximab + cyclophosphamide + doxorubicin hydrochloride + vincristine + prednisone
- Development stage
- Phase 3
- Lead developer
- Genmab
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
Epcoritamab + R-CHOP is an investigational combination regimen that adds the CD3xCD20 bispecific antibody epcoritamab (Epkinly) to standard R-CHOP chemoimmunotherapy (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone). Epcoritamab acts as a T-cell engager, redirecting CD3-positive T cells to target and eliminate CD20-positive B-cell lymphoma cells, while R-CHOP provides standard cytotoxic chemotherapy and anti-CD20 immunotherapy. The combination is being developed by AbbVie and Genmab for the first-line treatment of newly diagnosed diffuse large B-cell lymphoma (DLBCL). In the Phase III EPCORE DLBCL-2 trial, the addition of epcoritamab to R-CHOP demonstrated a statistically significant and clinically meaningful 51% reduction in the risk of disease progression or death compared to R-CHOP alone in patients with newly diagnosed DLBCL and an International Prognostic Index (IPI) score of 2 to 5.
- Other names
- ABBV-GMAB-3013 + R-CHOPEpkinly + R-CHOPEpkinly + rituximab + cyclophosphamide + doxorubicin hydrochloride + vincristine + prednisoneGEN3013 + R-CHOPepcoritamab + R-CHOPepcoritamab + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisoneepcoritamab + rituximab + cyclophosphamide + doxorubicin hydrochloride + vincristine + prednisoneepcoritamab-bysp + R-CHOPepcoritamab-bysp + rituximab + cyclophosphamide + doxorubicin hydrochloride + vincristine + prednisone
02
Targets
CD20 (B-lymphocyte antigen CD20)DNATOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)CD3 (T-cell surface glycoprotein CD3)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on epcoritamab + rituximab + cyclophosphamide + doxorubicin hydrochloride + vincristine + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epcoritamab + rituximab + cyclophosphamide + doxorubicin hydrochloride + vincristine + prednisone.